Functionality and antidiabetic utility of β- and L-cell containing pseudoislets

Area of Science:

• Cell Biology
• Endocrinology
• Transplantation Science

Background:

• Clinical islet transplantation faces challenges due to limited tissue availability and poor graft engraftment.
• Pseudoislets offer a potential solution by creating functional islet-like structures from cell lines.
• Investigating combined insulin and GLP-1 secreting cell lines for enhanced therapeutic outcomes.

Purpose of the Study:

• To evaluate the therapeutic potential of pseudoislets derived from MIN6 (insulinoma) and GLUTag (GLP-1 secreting) cell lines.
• To assess the viability, apoptosis, and in vivo efficacy of single-cell-type versus combined pseudoislets.
• To determine the impact of pseudoislet transplantation on glycemic control and pancreatic hormone profiles in diabetic mice.

Main Methods:

• Generation of pseudoislets from MIN6 and GLUTag cell lines, both individually and in combination.
• In vitro assessment of insulin secretion, viability, and apoptosis under various stress conditions.
• In vivo transplantation into streptozotocin-induced diabetic SCID mice, followed by analysis of glycemic control, body weight, and pancreatic hormone levels.

Main Results:

• Both MIN6 and GLUTag pseudoislets secreted insulin and GLP-1 in response to secretagogues.
• Combined pseudoislets demonstrated enhanced resistance to cytotoxic agents and reduced apoptosis compared to single-type pseudoislets.
• Transplantation of pseudoislets into diabetic mice improved glycemic control, insulin levels, and body weight, with combined pseudoislets showing tempered normoglycemia and improved β:α cell ratios.

Conclusions:

• Heterotypic pseudoislets combining insulin and GLP-1 secreting cells offer superior therapeutic benefits over single-cell-type pseudoislets.
• Combined pseudoislets exhibit increased resistance to apoptosis and promote better glycemic regulation and islet structure in vivo.
• This strategy holds promise for advancing cell therapy in type 1 diabetes by overcoming limitations of current islet transplantation methods.